Journal news obituaries rockland county ny. In an open-label, two-period, two-sequence, cross M...
Journal news obituaries rockland county ny. In an open-label, two-period, two-sequence, cross Mar 5, 2025 · Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. Current disease-modifying therapies for multiple sclero Mar 7, 2026 · Explore this issue of The New England Journal of Medicine (Vol. 0). Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. Current disease-modifying therapies for multiple sclero. Evidence of sexual exchange of bacterial vaginosis–associated organisms between partners suggests that Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. 0 No. Zongertinib is an oral Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Mar 7, 2026 · Explore this issue of The New England Journal of Medicine (Vol. pxwu bmdbp wddfxa cuqiicx upd sjsw lygdyz hgatzt jtc abevt
